ClinicalTrials.gov
public full text
Public Domain
Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure of all active drugs known to be effective.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer#1183056
- Combination Chemotherapy in Treating Patients With Colorectal Cancer#890844
- Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer#833341
- Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases#882906
- Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations#993142
Record · ID 1310296
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive